Heterocyclic Des1 Inhibitors for Selective Sphingolipid Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for dihydroceramide desaturase (Des1) to address diseases associated with excessive Des1 activity, such as cancer, inflammation, fibrosis, and metabolic disorders.
Innovation Solution
Development of compounds with Des1 inhibitory activity, represented by Formula (I′) and (I″), which interact with dihydroceramide desaturase to modulate sphingolipid biosynthesis and potentially treat diseases mediated by Des1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Des1 inhibitors are developed to treat diseases mediated by excessive Des1 activity, then therapeutic effectiveness is improved, but compound specificity and selectivity become critical challenges
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features at particular positions to achieve selective inhibition of Des1. The compounds contain a heteroaryl ring system with specific substituents at defined positions (R1-R6) that create localized interactions with the Des1 active site, enabling selective binding without affecting other desaturases. This localized structural optimization allows the compound to distinguish Des1 from other enzymes with similar functions.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor compounds, including the type of heteroaryl ring, the nature of substituents (R1-R6), and their positions. These parameter variations are optimized to achieve the desired balance between potency and selectivity. By adjusting these chemical parameters, the compounds can be fine-tuned to specifically target Des1 while maintaining therapeutic effectiveness.
2Adaptability or versatility
If compounds are designed to selectively inhibit Des1, then selectivity is improved, but compound complexity and synthesis difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor compound into distinct functional modules: a core heteroaryl ring system and multiple substituent positions (R1-R6). This modular structure allows for systematic optimization of selectivity through independent modification of each module. The segmented design enables researchers to adjust specific substituents to enhance Des1 selectivity without redesigning the entire molecule, thereby managing synthesis complexity.
Solution Approach 2:
The patent employs universality by designing a versatile heteroaryl core structure that can accommodate various substituents while maintaining the fundamental Des1 inhibition mechanism. This universal scaffold allows the same core structure to serve multiple purposes: providing the essential binding interactions with Des1 while allowing different substituents to fine-tune selectivity and pharmacokinetic properties. This multi-functional design simplifies the overall synthesis strategy compared to designing entirely different molecules for each selectivity requirement.
Data Source
AI summary
The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibriotic activity.